INT75682

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 1998
Last Reported 2010
Negated 0
Speculated 4
Reported most in Body
Documents 14
Total Number 18
Disease Relevance 10.24
Pain Relevance 5.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Chrna7) plasma membrane (Chrna7) cytoplasm (Chrna7)
Anatomy Link Frequency
muscle 2
bladder 1
fissures 1
limb 1
Chrna7 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Botox 70 100.00 Very High Very High Very High
Pain 112 99.84 Very High Very High Very High
Calcitonin gene-related peptide 11 99.52 Very High Very High Very High
Piles 46 99.40 Very High Very High Very High
depression 95 97.56 Very High Very High Very High
adenocard 2 97.48 Very High Very High Very High
headache 11 96.68 Very High Very High Very High
qutenza 3 96.16 Very High Very High Very High
GABAergic 5 95.36 Very High Very High Very High
Cluster headache 1 95.28 Very High Very High Very High
Disease Link Frequency Relevance Heat
Pain 74 99.84 Very High Very High Very High
Tremor 52 99.84 Very High Very High Very High
Overactive Bladder 8 99.84 Very High Very High Very High
Anorectal Disorders 50 99.40 Very High Very High Very High
Skin Appendage Disease 15 99.28 Very High Very High Very High
Dystonia 87 98.96 Very High Very High Very High
Parkinsonian Disorders 4 98.56 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 9 98.16 Very High Very High Very High
Neuromuscular Disease 4 97.76 Very High Very High Very High
Cervical Cancer 14 97.66 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Disruption of the cytoskeleton affected alpha7-nAChR mobility and cell surface expression, but not their ability to form clusters.
Regulation (affected) of alpha7-nAChR
1) Confidence 0.45 Published 2010 Journal PLoS ONE Section Abstract Doc Link 20634896 Disease Relevance 0.05 Pain Relevance 0.36
In this study we investigated the effect of intravesical BTX-A administration on CGRP immunoreactivity and bladder hyperactivity in an acetic acid induced bladder pain model in rats.
Spec (investigated) Regulation (effect) of BTX in bladder associated with pain, attention deficit hyperactivity disorder and calcitonin gene-related peptide
2) Confidence 0.44 Published 2004 Journal J. Urol. Section Abstract Doc Link 15371885 Disease Relevance 0.36 Pain Relevance 0.58
BTX is a safe and effective treatment for anal fissures.
Regulation (effective) of BTX in fissures associated with piles
3) Confidence 0.36 Published 2008 Journal Journal of Cutaneous and Aesthetic Surgery Section Body Doc Link PMC2840903 Disease Relevance 0.57 Pain Relevance 0.36
The healing rate is dependent on the BTX dosage.
Regulation (dependent) of BTX
4) Confidence 0.36 Published 2008 Journal Journal of Cutaneous and Aesthetic Surgery Section Abstract Doc Link PMC2840903 Disease Relevance 0.38 Pain Relevance 0.13
OBJECTIVES: To assess the effects of intravesical injection of botulinum toxin type A (BTX) on a model of detrusor overactivity induced by intravesical infusions of adenosine triphosphate (ATP) and capsaicin.
Regulation (effects) of BTX associated with adenocard, qutenza, overactive bladder and botox
5) Confidence 0.35 Published 2005 Journal Urology Section Abstract Doc Link 15780404 Disease Relevance 0.17 Pain Relevance 0.41
On the other hand, BTX injection into muscles has indirect effects on CNS activity.[1617]

BTX: EFFECTS ON PAIN

Regulation (effects) of BTX in muscles associated with pain
6) Confidence 0.33 Published 2008 Journal Journal of Cutaneous and Aesthetic Surgery Section Body Doc Link PMC2840887 Disease Relevance 0.72 Pain Relevance 0.86
Only antibodies against the heavy chain block the function of the neurotoxin.[32] Immunization seems to be a higher risk in younger patients receiving higher doses more frequently intramuscular like in neuromuscular diseases.[33] There has been no report so far on the induction of neutralizing or blocking antibodies in patients where BTX has been used for treatment of hyperhidrosis or for aesthetic reasons.[34]

SUMMARY

Regulation (used) of BTX associated with skin appendage disease, neuromuscular disease and immunization
7) Confidence 0.33 Published 2008 Journal Journal of Cutaneous and Aesthetic Surgery Section Body Doc Link PMC2840887 Disease Relevance 0.74 Pain Relevance 0.24
The efficacy of botulinum toxin (BTX) without systemic effects has led to the rapid development of applications in neuromuscular disorders, hyperactivity of sudomotor cholinergic-mediated glandular function, and pain syndromes.
Regulation (efficacy) of BTX associated with pain, syndrome, neuromuscular disease and attention deficit hyperactivity disorder
8) Confidence 0.25 Published 2004 Journal Mov. Disord. Section Abstract Doc Link 15027069 Disease Relevance 0.94 Pain Relevance 0.09
Statistical analysis was conducted using the Wilcoxon test and paired Student's t-test to compare the effect of Btx injection on the patients' symptoms scores or lower oesophageal pressure at the various time points.
Regulation (effect) of Btx
9) Confidence 0.22 Published 2002 Journal BMC Gastroenterol Section Body Doc Link PMC122056 Disease Relevance 0.09 Pain Relevance 0.03
Different mechanisms of influence of BTx on pain are discussed.
Regulation (influence) of BTx associated with pain
10) Confidence 0.20 Published 1998 Journal Neurol. Neurochir. Pol. Section Abstract Doc Link 9608554 Disease Relevance 0.84 Pain Relevance 0.73
We investigated the efficacy of botulinum toxin A (BtxA) therapy in patients with atypical parkinsonian disorders (APD) exhibiting different types of disabling focal dystonia unresponsive to oral drug therapy.
Spec (investigated) Regulation (efficacy) of BtxA associated with focal dystonia and parkinsonian disorders
11) Confidence 0.07 Published 2002 Journal J. Neurol. Section Abstract Doc Link 11993530 Disease Relevance 0.73 Pain Relevance 0
When injected at or near the motor point of affected muscle BTX binds to the SV2 receptor on the presynaptic membrane allowing for entry of the toxin into the axon terminal.
Regulation (affected) of BTX in muscle
12) Confidence 0.04 Published 2010 Journal Frontiers in Neurology Section Body Doc Link PMC3009478 Disease Relevance 0.71 Pain Relevance 0.04
In patients we studied the influence of BTX treatment on homeostatic plasticity modulated by the HFSLTP-LTD protocol before and one, two, and four weeks after BTX injections (Fig. 2).


Regulation (influence) of BTX associated with depression
13) Confidence 0.04 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2964285 Disease Relevance 0.31 Pain Relevance 0.26
Placebo controlled trials of BTX in essential tremor have shown that in some cases there is significant reduction of tremor amplitude, but only mild functional improvement associated with problematic limb weakness (Jankovic et al 1996; Brin et al 2001; Cordivari et al 2004).
Regulation (controlled) of BTX in limb associated with tremor
14) Confidence 0.04 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2546470 Disease Relevance 0.80 Pain Relevance 0.10
In our study there was not even a trend for a positive treatment effect after this single treatment session of BTX.
Regulation (effect) of BTX
15) Confidence 0.03 Published 2007 Journal J Neurol Section Body Doc Link PMC1915612 Disease Relevance 1.13 Pain Relevance 0.71
The influence of BTX on homeostatic control was investigated in the (HFSLTP followed by HFSLTD) protocol in BEB patients (Fig. 2).
Spec (investigated) Regulation (influence) of BTX associated with dystonia
16) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2964285 Disease Relevance 0.15 Pain Relevance 0.04
We therefore created S401 mutants with 12 substitutions (S401C,W,P,A,K,F,R,E,L,N,D,G) and assayed their BTX sensitivity.
Regulation (sensitivity) of BTX
17) Confidence 0.02 Published 2007 Journal Pflugers Arch. Section Abstract Doc Link 17205354 Disease Relevance 0 Pain Relevance 0.15
The aim of the study was to evaluate and compare health-related quality of life (HR-QoL) and depression in essential blepharospasm (BSP) and idiopathic cervical dystonia (CD), to identify the clinical and demographic factors associated with poor HR-QoL in both disorders and to analyse the effect of Botulinum Toxin A (BtxA) therapy.
Spec (analyse) Regulation (effect) of BtxA associated with cervical cancer, depression and dystonia
18) Confidence 0.00 Published 2002 Journal J. Neurol. Section Abstract Doc Link 12140667 Disease Relevance 1.53 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox